Savara (SVRA) Slides 2.78% as Peers Surge – Market Dynamics and Future Outlook
Savara’s stock slipped 2.78% to $4.54 as peers surged, revealing a shaky outlook for its rare respiratory therapies amid broader biotech volatility.
3 minutes to read
SAVARA INC
Savara Inc. (SVRA) Slides 1.9% as Phase‑2/3 Molgramostim Shows Lung Function Gains
Explore Savara Inc.’s latest market trend and breakthrough molgramostim data from the CHEST 2026 meeting—insights into rare respiratory therapy progress.
2 minutes to read
Savara (SVRA) Rises 4% to $4.63 Amid Market Volatility, 2026 Stock Update
Savara (SVRA) stock climbs 4.04% in Oct 2026, trading at $4.63 with a $1.1B market cap. Discover the latest performance, market trends, and insights for this clinical‑stage pharma leader.
One minute to read